High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir+ ribavirin and sofosbuvir/simeprevir/daclatasvir+ ribavirin in retreatment of chronic …
EM Said, BA Abdulaziz, M El Kassas, IH El Attar… - Archives of …, 2020 - Springer
Archives of Virology, 2020•Springer
The aim of this work was assessment of the efficacy and tolerability of two different regimens
for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based
therapy. This prospective study included 104 HCV patients who failed to respond to
SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and
tolerability were assessed. The 12-week sustained virological response (SVR12) rates were
96% and 94.4% in groups B and A, respectively, with no significant difference (p= 1.000) …
for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based
therapy. This prospective study included 104 HCV patients who failed to respond to
SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and
tolerability were assessed. The 12-week sustained virological response (SVR12) rates were
96% and 94.4% in groups B and A, respectively, with no significant difference (p= 1.000) …
Abstract
The aim of this work was assessment of the efficacy and tolerability of two different regimens for retreatment of hepatitis C virus (HCV) patients who failed to respond to SOF/DCV-based therapy. This prospective study included 104 HCV patients who failed to respond to SOF/DCV-based therapy. Patients were randomly allocated to two groups. Efficacy and tolerability were assessed. The 12-week sustained virological response (SVR12) rates were 96% and 94.4% in groups B and A, respectively, with no significant difference (p = 1.000). Most adverse events reported were mild to moderate, with no deaths during the study. Multi-target direct-acting antiviral (DAA) combinations are efficient for retreatment of HCV patients after failure of SOF/DCV-based therapy in real-world management.
ClinicalTrials.gov identifier: NCT02992457.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果